Expert Interviews

Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.

Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.

The panel shares some closing thoughts on ctDNA testing in patients with colorectal cancer.

The panel comments on how they see ctDNA assay usage evolving in colorectal cancer management.

Comprehensive insight on how best to communicate potential adverse events and followup strategies with patients going on therapy for RCC.

Hans Hammers, MD, PhD, provides a broad overview on the treatment options available to patient who receive a diagnosis of renal cell carcinoma.

Sandy Wong, MD, presents data from a subgroup analysis of the GRIFFIN and MASTER trials in patients with transplant-eligible NDMM.

Drs Lesokhin and Wong detail their strategies for maintenance therapy after transplant in NDMM treatment.

Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.

Experts on multiple myeloma discuss available BCMA-targeted CAR T-cell therapies and the KarMMa and CARTITUDE-1 clinical trials.

Noa Biran, MD, and David Siegel, MD, review the shifting treatment paradigms in multiple myeloma (MM).

Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.

Experts on breast cancer give an overview to treating PD-L1-positive triple-negative breast cancer.

Hope S. Rugo, MD, FASCO, discusses how BRCA mutations change the treatment approach for triple-negative breast cancer.

The panel continues their discussion of investigational triplet therapies in frontline RCC treatment.

Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.

The doctors review data from the COSMIC-313 trial investigating a frontline triplet therapy for advanced RCC.

Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.

An expert from the University of Texas Southwestern Medical Center discusses several phase 3 clinical trials supporting the use of various single-agent and combination immunotherapy regimens for advanced kidney cancer.

Insight from cardiologist Anees A. Daud, MD, following his viewing of AbbVie’s educational video on cardiovascular risk and androgen deprivation therapy.